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Geriatric Evaluation Programs and Elderly Oncology PatientsyDear Editor,
Quality of life and life expectancy are two important and
strongly linked aspects of old age. On one hand, the improvement
of economic and social conditions in the Western world has
resulted in an increase in average life expectancy, but on the other
hand, progressive aging has shed light on the intrinsic frailty of the
older population. It is already known that advanced age correlates
not only with an increase in chronic diseases and disabilities but
also with an increase in cancer cases. In the past, tumors in elderly
patients were, at times, underestimated and undertreated. The
doctors not only mistakenly believe that cancer in the elderly was
less aggressive and grew more slowly but also that the patient’s
advanced age was a sufﬁcient reason for nontreatment1. Fortu-
nately, the recognition of the dignity of the elderly and their rights
to be treated has led, in the course of the last decade, to the creation
of models for multidimensional geriatric evaluation (MGE), useful
instruments for putting all the complexities of the elderly and the
oncology patient into perspective.
There is no doubt that the biggest challenge we face today is to
discern which of our elderly oncology patients will beneﬁt from
aggressive therapies and which will beneﬁt from supportive care
only2. This difﬁculty is attributed partially to the rarity of published
studies that had used MGE as an integral part of the decision
making3,4. We cannot underestimate how much this lack notably
weighs on the validity of MGE, and it reﬂects that its use in clinical
practice is still not very structured and is even a bit ambiguous. To
this, we can add the uncertainty that still exists about which ther-
apeutic approach to use for older cancer patientsduncertainty that
translates into less-than-optimal or excessively toxic treatments or
in a poorer outcome than younger patients5.
Studies on MGE in this category of patients have demonstrated
how the functional state of the patients predicts their probability of
survival, toxicity of the chemotherapy, posttreatment vulnerability,
and mortality6–9. The presence of a serious comorbidity, in fact,
goes along with a particularly unfavorable prognosis for an
oncology patient 2,10–14. This leaves us asking why a patient who
is considered frail, therefore largely prone to serious toxicity during
the therapy and thereafter, with serious disabilities and a lower
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criteria of frailty established by using MGE? Perhaps, at the root
of this problem is a subjective interpretation of the patient’s frailty?
Does a common deﬁnition of frailty exist?
Exemplary of this is a retrospective study conducted by Basso
et al15 on 117 elderly patients (with an average age of 75 years)
suffering from cancer. All of them were slated to receive either
adjuvant or neoadjuvant chemotherapy or chemotherapy for meta-
static disease. Among these 117 patients, 40 (34.2%) were frail.
Although there were no differences in the use of the “elderly-
friendly” treatment among the frail and nonfrail (40% of frail
patients and 39% of nonfrail patients), in the dose reduction greater
than or equal to 25% (37.5% vs. 31.2%), in 3- to 4-grade toxicity
(52.5% vs. 58.4%), there were remarkable differences between the
groups in the percentages of premature interruption of treatment
because of toxicity or the patient’s refusal (42.5% vs. 15.6%) and
the deaths within 30 days of the last dosage of the chemotherapy
(22.5% vs. 3.9%). This demonstrates that the frail patients had
obtained beneﬁts from the treatment that were notably lesser not
only in terms of tumor response (21.2% vs. 44.3% in 94 evaluated
patients) but also in terms of clinical beneﬁts (22.6% vs. 45.8% in
90 evaluated patients)15.
In light of these results, it is natural to ask ourselves why frail
patients should be subjected to therapy if a comorbidity or real
disabilities are present. Perhaps, because external requests coming
from the family or the patients themselves, even rightly so, inter-
fere with the doctor’s choice, inﬂuencing the therapeutic approach
and rendering it more aggressive? Perhaps, because the current
criteria of frailty do not fully contemplate the real heterogeneity
in the phenotype of the elderly patient16, presenting the risk of
erroneously classifying the patient?
Therefore, frailty cannot be seen only as a physiological state
resulting from a general decline of the body and of the deregulation
of different metabolic systems17,18, but instead, should be consid-
ered a syndrome, meaning a cumulative effect of deﬁciencies in
many areas (social, cognitive, physiological, biological), which
together resolve into a particular adverse outcome19–23.
Surely, the introduction of MGE has improved the approach to
the elderly cancer patient, but we believe that it has not substan-
tially impacted the management of the same. First of all, only
a small number of oncology physicians has begun to use this
new way of interacting with the elderly24; in fact, a complete
MGE is rarely used in clinical practice by those who are inter-
ested in taking care of the elderly patient, and this can be attrib-
uted to the additional time that MGE requires25. On the other
hand, the administration of various questionnaires takes place
with different methods and at times that vary among differenty & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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the ﬁrst visit27; there are no studies that claim that MGE should
be repeated at a later time during the treatment, and this, in our
opinion, is a serious mistake. Every individual is a dynamic entity,
and as such, is prone to changes and modiﬁcations in their health
over time. This means that an oncology patient can experience
changes in his or her condition not only in consequence to his
or her disease but also to the treatment, and these alterations
should be closely monitored. MGE should become a valid method
of support in that sense and should be repeated also at the
moment of the ﬁrst reevaluation, at the end of the therapy, and
during the next follow-up. This way, it can reveal potential signs
for concern and allow the doctors to modify therapeutic decisions
accordingly.
The comprehension of the diverse factors in the vulnerability of
the elderly population and the unequivocal coding of the frailty can,
in our opinion, offer new opportunities in terms of prevention as
well as in promotion of good health and better assistance. However,
it is of fundamental importance that the recognition of a situation
of frailty is accompanied by an adequate therapeutic choice, at all
costs avoiding putting a frail patient through chemotherapy,
keeping inmind that these patients already have a very unfavorable
prognosis and a high risk of developing serious toxicities. The
deciding moment for the use of MGE should be, therefore, well
planned: Through this, the doctor should be able to evaluate for
every patient all the resources that he could put into use for facing
both the disease and the treatment, to and prevent causing unnec-
essary decline of the quality of life of the elderly patient. Only when
MGE really becomes a part of daily clinical practice and gets taken
into consideration more in the choice of therapies, we could
consider it a truly useful tool. Senior adult guidelines of NCCN27
can offer, together, comprehensive geriatric assessment that
provides the possibility to choose the most appropriate treatment
for geriatric cancer patients.
In recent times, multiple clinical trials have investigated the
safety and efﬁcacy of metronomic chemotherapy in a variety of
human cancers. Although the results have been variable, clinical
studies have shown that these new treatment protocols represent
an interesting alternative for either primary systemic therapy or
maintenance therapy, and they are a possible option for the elderly
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